On Wednesday, April 9 through Saturday, April 12, at the annual meeting ofthe International Society for Heart and Lung Transplantation (ISHLT) Meetingin Boston, MA, an additional six presentations will report on studies of theuse of the ImmuKnow assay in a variety of heart and lung transplantrecipients:

Thursday, April 10 -- "Use of an immune monitoring assay to distinguish between fungal colonization and fungal disease in lung transplant recipients" (S. Husain, J. Pilewski, K. Spichty, et al.) -- oral presentation, 4:15 p.m. - 5:45 p.m. (Oral Session: Management of Emerging Infection in Heart and Lung Transplantation) -- "Immune cell function testing for the optimization of the therapeutic drug monitoring in selected heart transplant patients, a case series" (T. Ben Gal, V. Yaari, M. Israeli, et al.) -- poster presentation, 5:45 p.m. - 6:45 p.m. (General Posters: Poster Session II) Friday, April 11 -- "Success of immune monitoring with ImmuKnow (Cylex) to assess rejection/infectious risk in heart transplantation" (J. A. Kobashigawa, K. K. Kiyosaki, J. K. Patel, et al.) - oral presentation, 10:45 a.m. -- 12:45 p.m. (Oral Session: Can We Predict, Diagnose and Treat Cardiac Rejection and Vasculopathy Before It's Too Late?) -- "Assessment of the Cylex ImmuKnow cell function assay in pediatric heart transplant patients" (J. W. Rossano, S. W. Denfield, E. O. Smith, et al.) -- oral presentation, 10:45 a.m. - 12:45 p.m. (Oral Session: The Long and the Short of Pediatric Immunosuppression and Immunology) -- "Low Cylex immune response associated with increased infection in pediatric heart transplants" (A. P. Barnes, S. M. Daneman, K. J. Guleserian, et al.) -- poster presentation, 5:45 p.m. - 6:45 p.m. (General Posters: Poster Session III) -- "Monitoring for PTLD in children after lung transplantation" (O. Elidemir, B. S. Kancheria, M. G. Schecter, et al.) -- poster presentation, 5:45 p.m. - 6:45 p.m. (General Posters: Poster Session III) The various studies report on the clinical use of the ImmuKnow immunefunction assay in adult and in pediatric patients. The use of the ImmuKnowassay for identification of patients as described in some of these studies hasnot been cleared by the U.S. Food & Drug Administration (FDA). The company mayuse data from these or similar studies to support future FDA marketingapplications.

About ImmuKnow(R)

ImmuKnow is an immune cell function assay that can detect cell-mediatedimmunity (CMI) in adult immunosuppressed patients by measuring theconcentration of adenosine triphosphate (ATP) released from CD4 cellsfollowing cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantifythe level of immunosuppression. Results of ImmuKnow assays should be used inconjunction with clinical presentation, medical history, and other clinicalindicators when assessing the immune status of any individual patient. The useof the ImmuKnow assay as described in these studies has not been cleared bythe FDA. The company may use data from these or similar studies to support afuture FDA marketing application for a similar indication.

ImmuKnow is a product of Cylex(TM), a privately held global life sciencescompany and the leader in the development and manufacture of research and invitro diagnostic products intended to assist in the assessment of immunefunction.

About Cylex(TM) Inc.

Cylex(TM) is a privately held global life sciences company that is theleader in the development and manufacture of in vitro diagnostic products thatare intended to illuminate immunity. ImmuKnow(R) is the in vitro diagnosticutilized to detect cell-mediated immunity (CMI) in an immunosuppressedpopulation, and is increasingly being adopted at organ transplant centersthroughout the US and abroad. The Company's patented technology provides aninnovative platform allowing clinical researchers to simply and reproduciblymeasure CMI for the development of new diagnostics, biomarkers and companionassays. The Company is based in Columbia, MD.

SOURCE Cylex Inc.